chevron_leftBack
As of 24 April 2025, NovoCure Ltd. has a market cap of $1.95B USD, ranking #5419 globally and #175 in the United Kingdom. It ranks #494 in the Healthcare sector, and #50 in the Medical Devices industry.
Key Stats
Market Cap
$1.95BUSD
Enterprise Value
$1.68BUSD
Revenue (TTM)
$605.22MUSD
EBITDA (TTM)
-$157.67MUSD
Net Income (TTM)
-$168.63MUSD
EBITDA Margin
-26%
Profit Margin
-28%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Ashley Cordova
open_in_new
Employees
1,488
Founded
2000
IPO
02 Oct 2015
Website
novocure.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 7.6% | 12% | -8.5% | -34% | 9.6% | 50% |
Upcoming Earnings
Earnings Date
Thu, Apr 24
Today
Earnings Time
sunny
Before Open
EPS Estimate
-$0.4600
Revenue Estimate
$147.0M
6.1% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NVCR
NovoCure Ltd
ISIN: JE00BYSS4X48
Shares Out.:
Shares Outstanding:
111.485M1
Shares Float:
99.747M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
17.77 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
